Evidence-informed pharmacology monograph updated 10 November 2026. For education only; use current local labeling, clinical guidance and individual assessment.
Overview
Acetazolamide is a systemic sulfonamide carbonic anhydrase inhibitor, used for altitude illness prophylaxis/treatment, selected glaucoma indications, intracranial hypertension, epilepsy and certain edema or alkalosis scenarios. It is a relatively weak diuretic compared with loop diuretics and has important acid–base effects. Evidence and authorization differ by indication [1,2].
Mechanism by organ system
Carbonic anhydrase catalyzes CO2 hydration to bicarbonate and hydrogen ions. In the kidney, inhibiting proximal-tubule carbonic anhydrase reduces bicarbonate reabsorption and causes bicarbonaturia, increased urine pH and a hyperchloremic metabolic acidosis. In the eye it lowers aqueous humor formation; in the CNS it reduces cerebrospinal fluid production and stimulates ventilation through metabolic acidosis. It does not directly act as an osmotic diuretic [1].
Altitude illness and prevention
Acetazolamide speeds acclimatization by promoting ventilation and may reduce acute mountain sickness during rapid ascent; gradual ascent remains preferable. Adult prophylaxis commonly uses 125 mg twice daily starting before ascent and for the first days at altitude, but specific clinical protocols and renal function determine dose. It is not a substitute for descent, oxygen or emergency management in severe altitude-related brain or pulmonary illness [1,2].
Other clinical indications
Systemic acetazolamide can be an adjunct for ocular pressure management in appropriate glaucoma cases and is used in selected idiopathic intracranial hypertension patients, usually alongside weight management when indicated. It may help correct chloride-resistant metabolic alkalosis or enhance natriuresis in selected acute heart-failure patients under monitored care. The drug is not a general recommendation for all patients with CKD; significant renal dysfunction can cause accumulation and worsen acidosis [1,2].
Pharmacokinetics and precautions
The medicine is orally or intravenously administered, is not extensively metabolized and is mainly eliminated unchanged by kidneys. Tingling/paresthesias, dysgeusia, polyuria, fatigue, nausea, low potassium/sodium, metabolic acidosis and kidney stones may occur. Rare severe sulfonamide-associated skin or blood reactions require prompt discontinuation [1,2].
Contraindications and interactions
The 2025 DIAMOX label contraindicates use with depressed sodium or potassium, marked kidney or liver disease, adrenal insufficiency, hyperchloremic acidosis and cirrhosis because of hepatic encephalopathy risk. High-dose aspirin combined with acetazolamide has been associated with serious acidosis and neurologic toxicity. Check serum bicarbonate, electrolytes and renal function when clinically indicated; avoid assuming the drug is harmless merely because diuresis is moderate [2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- US Food and Drug Administration. DIAMOX (acetazolamide) prescribing information, revised 2025. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/008943s054lbl.pdf
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.